Imeik Technology Development
300896.SZImeik Technology Development is a leading player in China's medical aesthetics market, focusing on injectable hyaluronic acid (HA) fillers and other regenerative medical products. The company went public on the Shenzhen Stock Exchange's ChiNext board in 2020, achieving significant market capitalization. Its core strategy involves continuous R&D to expand its product portfolio and maintain its competitive edge in the domestic aesthetic medicine sector, while also exploring international expansion opportunities.
300896.SZ · Stock Price
Historical price data
AI Company Overview
Imeik Technology Development is a leading player in China's medical aesthetics market, focusing on injectable hyaluronic acid (HA) fillers and other regenerative medical products. The company went public on the Shenzhen Stock Exchange's ChiNext board in 2020, achieving significant market capitalization. Its core strategy involves continuous R&D to expand its product portfolio and maintain its competitive edge in the domestic aesthetic medicine sector, while also exploring international expansion opportunities.
Technology Platform
Proprietary platform for developing and manufacturing differentiated hyaluronic acid (HA) gels using advanced cross-linking technologies to create dermal fillers with specific physical properties for various aesthetic indications.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Imeik competes directly with global leaders like Allergan (Juvéderm) and Galderma (Restylane), as well as major domestic players like Bloomage BioTechnology. Its differentiation lies in cost-competitiveness, products tailored for Asian anatomy, and strong local distribution networks.